Skip to main content

Advertisement

Table 2 Baseline demographics and clinical characteristics for the influenza vaccination population

From: Antibody response to pneumococcal and influenza vaccination in patients with rheumatoid arthritis receiving abatacept

Characteristic Influenza vaccine population (N = 191)
Age
 Mean (SD), years 44.9 (12.6)
Sex
 Women, n (%) 172 (90.1)
 Men, n (%) 19 (9.9)
Race
 White, n (%) 188 (98.4)
 Black/African American, n (%) 2 (1.0)
 Other, n (%) 1 (0.5)
Region
 South America, n (%) 156 (81.7)
 North America, n (%) 35 (18.3)
Weight
 Mean (SD), kg 68.4 (17.3)
Duration of abatacept exposure during main study
 Mean (SD), months 37.6 (2.9)
Tender joint count/28
 Mean (SD) 30.7 (14.4)
Swollen joint count/28
 Mean (SD) 20.3 (8.0)
Patient pain
 100-mm VAS, mean (SD) 65.5 (22.2)
HAQ-DI
 Mean (SD) 1.7 (0.6)
C-reactive protein,
 Mean (SD), mg/dL 2.4 (2.7)
Patient global assessment
 100-mm VAS, mean (SD) 64.7 (21.5)
Physician global assessment, 100-mm VAS
 100-mm VAS, mean (SD) 60.3 (17.9)
DAS28 (C-reactive protein)
 Mean (SD) 6.3 (0.8)
Concomitant methotrexate
n (%) 186 (97.4)
  1. DAS28 Disease Activity Score 28, HAQ-DI Health Assessment Questionnaire-Disability Index, SD standard deviation, VAS visual analog scale